Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease

Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behcet's disease (BID) are still not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic disorders. We studied plasma TAR levels in BD in comparison with healthy controls.